Building intelligent networks that connect global expertise, computational models, and experimental capabilities. Our platform integrates dynamic discovery flows, continuous learning loops, and strategic deployment to accelerate therapeutic development.
Our platform is built from the ground up as an AI-native system, creating intelligent networks that connect global expertise, computational models, and experimental capabilities. This reveals optimal collaborations and breakthrough opportunities that traditional siloed approaches cannot identify.
Each collaboration teaches the network how to form better connections, transforming drug discovery into a continuously improving, distributed intelligence. Our system doesn't just learn about molecules—it learns how to optimize the innovation process itself.
Our network-based approach unlocks powerful effects where each new participant makes the entire system exponentially more capable at discovering breakthrough medicines. The network grows smarter with every interaction.
Our platform leverages state-of-the-art AI architectures:
Built on modern architectural principles:
Comprehensive integration across:
We coordinate a distributed network of world-class talent, cutting-edge technologies, and leading institutions. Our in-house capabilities are amplified through strategic partnerships with:
Built from the ground up with AI/ML at the core. Our computational infrastructure spans across our network, enabling distributed processing and model deployment.
Seamless coordination of distributed capabilities through our orchestration platform, ensuring efficient resource allocation and communication across all network nodes.
We pursue portfolios by indication through focused "Answer Projections" - TAP Neuro, TAP Oncology, and others. These are agile sprinter groups formed to concentrate efforts around specific initiatives. We dynamically create new Answer Projections as opportunities emerge, enabling rapid deployment of our platform across diverse therapeutic areas.
Parallel processing across our network accelerates discovery timelines. Our learn-fast/kill-fast approach enables rapid decision-making and program advancement.
Continuous flow from target discovery through preclinical and clinical development, with computational predictions guiding each stage.
Every experimental result feeds back into our AI models, creating a continuous learning loop that improves predictive accuracy across our entire network.
Rapid empirical validation of computational predictions, with results immediately informing model refinement and next-round predictions.
Iterative refinement of both computational models and experimental approaches, continuously improving the accuracy and efficiency of our discovery process.
Active engagement with pharmaceutical partners, leveraging our platform to accelerate and de-risk their development programs.
Seamless transition from discovery to clinical development through our network of clinical research organizations and medical institutions.
Strategic commercialization through established industry networks, ensuring successful market access and therapeutic deployment.
Our platform orchestrates a global network of computational and experimental capabilities, enabling seamless integration of AI-driven predictions with rapid empirical validation.
Every experimental result feeds back into our AI models, creating a continuous learning loop that improves predictive accuracy across the entire network.
Seamless transition from discovery to development through our network of clinical research organizations and industry partners.
Founder • Distributed Innovation • Entrepreneur, Impact Investor
Special Assistant to the President, Biological Threats • Managing Director/Partner, BCG, PwC • Operation Warp Speed architect
Corporate and Technology Strategy • Entrepreneur, Co-Founder ValueAI Institute • Investor, Venture Partner
Senior Pharma Leadership • AI-driven Drug Discovery, Portfolio • Platform Technology and Science, GSK
Machine Learning, Deep Learning • AI Researcher/Instructor, Berkeley, NASA • Founder, Silicon Valley Bank AI Lab
Head of Operations, SaponiQx • Novavax Vaccine Lead, US Government Operation Warp Speed • Technology Selection and Clinical Evaluation, Department of Defense
Machine Learning, Computational Biology, Cancer Genomics • CSO / CTO, Cancer IQ
Medical Strategy • CMO, ADC Therapeutics • SVP, Celgene, Pfizer, Wyeth
Neuroscience, Brain Plasticity • Professor, Harvard Medical School • Massachusetts General Hospital, BROAD Institute
Chief Security Officer, Cloudflare • CISO, McAfee, HSBC, Silicon Valley Bank
DNA Encoded Libraries • Informatics & Molecular Biology, Dice Therapeutics
Medicinal Chemist • Director, Exelixis • Principal Scientist, Merck
Neurology, Behavior, Psychiatry • Professor, UC Irvine, Neurobiology • Chief Scientific Officer, Signa Tx
Neuroscience, Cognitive Aging, Memory • Professor, University of Florida
Management Systems • High Performance Organization • Senior Lecturer, MIT Sloan
Lab Operations • Director of Facilities, Moderna • Operations, GSK, AstraZeneca
Life Sciences Strategy & Business Operations • Supply Chain, Project Management • Boston Consulting Group
Senior Pharma Leadership • Collaborative Drug Discovery, InnoCentive • R&D Executive, Eli Lilly
Life Sciences Entrepreneur • Co-founder, Episode 1, MOMA • EIR, Third Rock Ventures • Faculty, Harvard Medical School
TAP engages with partners by referral.